Johnson & Johnson (JNJ) Stock Could Be 7.3% Undervalued Based On Its Pharma And MedTech Focus

Johnson & Johnson (JNJ) is back in focus after recent share price weakness, with the stock down 2% over the past month and about 3% over the past 3 months, prompting fresh interest in its valuation.

See our latest analysis for Johnson & Johnson.

Despite the recent share price weakness over the past week and quarter, Johnson & Johnson’s year to date share price return of 10.15% and 1 year total shareholder return of 56.28% point to momentum that has been positive overall.

If this kind of move has you rethinking your sector exposure, it could be a good moment to broaden your watchlist with a healthcare focused AI stock screen such as 40 healthcare AI stocks

So with Johnson & Johnson now trading below its recent highs yet still carrying what some investors may view as a strong long term return profile, are you looking at an undervalued healthcare giant or a stock where the market already prices in future growth?

Most Popular Narrative: 7.3% Undervalued

At a last close of $228.39, the most followed narrative on Johnson & Johnson suggests a fair value of $246.46, framing the stock as modestly undervalued on that view.

Johnson & Johnson represents a high-quality, defensive healthcare leader with resilient earnings, strong cash flow generation, and disciplined capital allocation. Following the Kenvue spin-off, JNJ is now more focused on higher-margin Pharmaceutical and MedTech segments, improving long-term growth visibility.

Read the complete narrative.

Curious what justifies that higher fair value for Johnson & Johnson? The narrative leans on steady revenue expansion, thick margins, and a future earnings profile that assumes consistency rather than rapid growth. The key consideration is how those cash flows stack up over time and what kind of earnings multiple this healthcare company could support.

Result: Fair Value of $246.46 (UNDERVALUED)

Have a read of the narrative in full and understand what’s behind the forecasts.

However, Johnson & Johnson still faces risks such as litigation outcomes and pricing pressure in key therapies, which could challenge the current undervalued narrative.

Find out about the key risks to this Johnson & Johnson narrative.

Another View: Johnson & Johnson Through the P/E Lens

The narrative pegs Johnson & Johnson as about 7.3% undervalued at $246.46, but the earnings multiple tells a tighter story. At a P/E of 26.1x, the stock sits well above the US Pharmaceuticals average of 14.8x and almost on top of its 26.4x fair ratio and 26.2x peer average. That suggests much less obvious upside and raises a simple question for you as an investor: is the premium comfort, or is it crowding out future return potential?

See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

Mixed messages on Johnson & Johnson so far? Take a closer look at the data, weigh the risks against the rewards, and shape your own conviction using the 3 key rewards and 1 important warning sign

Looking for more investment ideas beyond Johnson & Johnson?

If Johnson & Johnson has sharpened your focus on quality, do not stop here. Broaden your watchlist with other focused ideas that could suit different roles in your portfolio.

This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com